Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
- October 02nd, 2023
- 605 views
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment of Clostridioides difficile infection (CDI).
The decision was due to the trial's success, with high clinical cure rates observed across the trial without any safety concerns for both ibezapolstat and the control antibiotic vancomycin.
This achievement has prompted the company to expedite its plans for Phase 3 clinical trials for this first-in-class antibiotic product candidate, which has earned FDA QIDP/Fast Track designation.
$ACXP was trading at $1.81 in pre-market, reflecting a remarkable increase of $0.38 (+26.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
September 04th, 2026Signing Day Is Not the End of Recruiting
September 04th, 2026Treasury, IRS Move to End Tax-Exempt Status for Discriminatory Practices in Private Schools
September 03rd, 2026FDA Approves First Drug to Treat Alexander Disease
September 03rd, 2026How Coaching Staffs Evaluate Athletes Across a Season
September 03rd, 2026
Member Login